NEWS UPDATE

DRUP the Drug Rediscovery Protocol

DAP DRUG Access Protocol

#85 May/June 2023

Contents go to >

DRUP and DAP Study Updates

As mentioned before, the newsletter of the DRUP and the DRUG Access Protocol (DAP) will be combined from now on.
To date, 2577 cases have been submitted to the DRUP study, of which 1374 (53%) have started a treatment (Table 2).

DRUG Access Protocol

For those who are not familiar with DAP, this protocol aims to facilitate access to targeted cancer therapies, which are not yet approved for reimbursement. By providing access to these therapies, data on effectiveness and safety are collected for these therapies while waiting for approval.

To date, 242 cases have been submitted to DAP, of which 198 (82%) have started with one of the 7 treatments (Table 2).

Study team

We are happy that Ilse Spiekman is back from her maternity leave, after her son Finn was born on 21st of December, 2022.

We have also welcomed Femke Verwer as a new team member and she will briefly introduce herself:

Hi, I am Femke Verwer, and I started as of May 1st at the NKI-AvL. Together with Emilie van der Sande I will work as a Clinical Projects Manager on the DRUP and the DAP study. Before I came to the NKI-AvL I worked in a similar position at the Princess Máxima Center for pediatric oncology. I look forward to apply my experience to these beautiful projects!

Scientific output

We are pleased to announce that the following abstracts are accepted for a poster presentation at ASCO 2023:

1) "Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with Cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials" by Laurien Zeverijn;

2) "Efficacy and predictors of response of nivolumab in treatment-refractory MSI solid tumors: results of a tumor-agnostic DRUP cohort" by Birgit Geurts.

Digital submission forms for DRUP and DAP

In the near future we plan to introduce digital forms for submitting a new patient to the DRUP and DAP studies. These forms will replace the submission of new patients via email as is currently done. With these forms, we aim to collect the patient information in an easier and more efficient way for all parties. More information about this procedure will be provided soon.

Best regards,

the Study team

Sponsor Study team	
Principal Investigators DRUP	Emile Voest (NKI-AVL), Henk Verheul (Erasmus MC), Hans Gelderblom (LUMC),
Principal Investigators DAP	Emile Voest (NKI-AVL), Haiko Bloemendal (Radboud UMC), Egbert Smit (LUMC)
Study Coordinators	Laurien Zeverijn, Birgit Geurts, Ilse Spiekman, Karlijn Verkerk, Georgy Gomon, Soemeya Haj Mohammad
Clinical Project Managers	Femke Verwer, Emilie van der Sande
Clinical Trial Assistant	Marion Bleijendaal
Contact:	
DRUP	DRUP@nki.nl
DAP	drugaccess@nki.nl

Calendar	
June 2 – 6, 2023	ASCO Annual Meeting (Chicago)
June 27, 2023	IDMC meeting
September 17 – 19, 2023	NPCM (Oslo)
October 20 – 24, 2023	ESMO congress (Madrid)

Publications	
Geurts *et al.* *BMC Cancer (2023) 23:205*	Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

DRUP				DRUG Access	
Currently available				**Currently available**	
Amgen Panitumumab	Eisai Lenvatinib	MSD Pembrolizumab	Roche Erlotinib Trastuzumab+ Pertuzumab Vemurafenib+ Cobimetinib Vismodegib Atezolizumab+ bevacizumab Alectinib Entrectinib	Sanofi Cemiplimab	Roche Entrectinib
BMS Nivolumab Ipilimumab	AstraZeneca Olaparib Durvalumab	Lilly Abemaciclib Selpercatinib		Bayer Larotrectinib	Lilly Selpercatinib
Novartis Dabrafenib Nilotinib Trametinib Alpelisib	Pfizer Axitinib Crizotinib Sunitinib Talazoparib Dacomitinib Lorlatinib	Janssen Erdafitinib		Merck Tepotinib	Janssen Amivantamab
Committed					
GSK Niraparib	Merck Tepotinib				

Table 2: Submission and accrual overview
May 1st, 2023

DRUP stage 1,2 & 3 cohorts

Submitted	2577
Enrolled	1374 (53%)



DRUG Access

Submitted	242
Started treatment	198 (82%)



Table 3: European collaboration

Country	Registration nr	Trial name	Status
The Netherlands	NCT02925234	DRUP	Opened for inclusion since Q3 2016
Denmark	NCT04341181	ProTarget	Opened for inclusion since Q3 2020
Sweden	NCT04185831	MEGALiT	Opened for inclusion since Q4 2020
Norway	NCT04817956	IMPRESS	Opened for inclusion since Q2 2021
Finland	NCT05159245	FINPROVE	Opened for inclusion since Q1 2022
France	NCT02029001	MOST Plus	Opened for inclusion since 2014
United Kingdom	NCT05722886	DETERMINE	Opened for inclusion since Q2 2023
Portugal		POP	Just finished protocol
Germany			In progress

For questions contact our teams at:
drup@nki.nl or call: 020-512 7848
drugaccess@nki.nl

Voor meer informatie: www.cpct.nl

Wilt u deze nieuwsbrief niet meer ontvangen?
dan kunt u hier afmelden